New drug renews hopes of Alzheimer's and depression

In Canada, experts have developed a new drug that will restore hope in the treatment of amnesia and mental disabilities that often affect the elderly, as well as depression.

Researchers in Toronto believe that this drug can help people with depression, schizophrenia and Alzheimer's disease because it is designed to treat nerve cells and brain nerves damaged by mental illness.

The new drug, derived from the benzodiazepine, targets specific receptors located on neurons in key parts of the brain involved in perception.

In a report published by the newspaper "The Guardian" and translated "Arab"The drug can be taken daily as a tablet for people over the age of 55. Clinical trials have shown that it is safe and effective in preventing memory deficits and that it should to be marketed within two years. "

Laboratory tests showed that older mice had much better memory capacity half an hour after receiving the drug. After two months of treatment, the researchers found that the reduced brain cells returned to normal, as did the younger mice.

Treatment is not just about the "normal" cognitive decline that occurs in older people, but it can also help treat the memory loss and mental disabilities that usually affect people with depression and schizophrenia, "he said. Etienne Sebel, a member of the Center for Addiction and Mental Health Toronto, "He said. Emphasizing that this target group is the age group between 55 and 65 years old, as it presents a risk of cognitive problems.

Read also: Exercise secretes a hormone that protects against Alzheimer's disease

Siebel, one of the participants in the study, noted that the global drug market lacks a drug that can prevent memory loss related to aging and psychological disorders such as depression and schizophrenia. Noting that the new drug also prevents memory loss in the early stages of Alzheimer's disease and may delay its onset.

Researchers presented the drug Wednesday at the annual meeting of the American Association for the Advancement of Science in Washington, DC, and hope to be tested on humans and help solve the problems of memory disorders, depression and disability mental.